PROTACs and Molecular Glues for Neurodegeneration

📖 Wiki Page

therapeutic951 wordssynced 2026-04-02

PROTACs and Molecular Glues for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PROTACs and Molecular Glues for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Physicochemical optimization</td>
<td>Lipophilicity, HBD/HBA optimization</td>
</tr>
<tr>
<td class="label">Prodrug approaches</td>
<td>Brain-targeted prodrugs</td>
</tr>
<tr>
<td class="label">Nanoparticle delivery</td>
<td>Lipid nanoparticles, [exosomes](/entities/exosomes)</td>
</tr>
<tr>
<td class="label">Focused ultrasound</td>
<td>BBB opening for enhanced delivery</td>
</tr>
<tr>
<td class="label">Receptor-mediated transcytosis</td>
<td>BBB shuttle molecules</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ARV-102</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">Tau PROTAC</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">α-Syn PROTAC</td>
<td>α-Synuclein</td>
</tr>
<tr>
<td class="label">mHTT PROTAC</td>
<td>Mutant [HTT](/proteins/huntingtin)</td>
</tr>
<tr>
<td class="label">Dual PROTAC T3</td>
<td>Tau + α-Syn</td>
</tr>
</table>

...

PROTACs and Molecular Glues for Neurodegeneration

Overview

PROteolysis-TArgeting Chimeras (PROTACs) and molecular glue degraders represent a transformative therapeutic modality for neurodegenerative diseases. Unlike traditional small-molecule inhibitors that block protein function, these degraders recruit the cell's own [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) to selectively eliminate disease-causing proteins. This page provides a comprehensive analysis of this technology applied to [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related neurodegenerative disorders.

Mechanism of Action

PROTAC Heterobifunctional Degraders

PROTACs are chimeric molecules consisting of three critical components:

Target-binding ligand (warhead): Binds specifically to the disease protein

E3 ubiquitin ligase recruiter: Binds to an E3 ligase (commonly [cereblon](/proteins/crbn) or VHL)

Chemical linker: Connects the two binding moieties

Mermaid diagram (expand to render)

Molecular Glue Degraders

Molecular glues are monovalent compounds that stabilize protein-protein interactions between a target protein and an E3 ligase, inducing degradation without the need for bifunctional design[@klein2024]. They offer:

Smaller molecular weight (typically 300-500 Da vs 700-1000 Da for PROTACs)
Better drug-like properties including CNS penetration
Novel binding modes not accessible to traditional PROTACs

The prototypical molecular glues are thalidomide analogs (lenalidomide, pomalidomide) that redirect [cereblon](/proteins/crbn) E3 ligase activity toward neo-substrates.

CNS Targets for Neurodegeneration

Tau Protein (Alzheimer's Disease and Tauopathies)

[Tau](/proteins/tau) pathology is the strongest correlate of cognitive decline in [Alzheimer's disease](/diseases/alzheimers-disease). PROTACs offer unique advantages over other [tau](/proteins/tau)-targeting approaches:

Intracellular access: Majority of pathological tau is intracellular, inaccessible to antibodies
Catalytic clearance: Single PROTAC molecule can degrade multiple tau copies
Conformer selectivity: Can be engineered to preferentially bind pathological phosphorylated forms

Arvinas tau PROTAC program: Preclinical studies demonstrate degradation of multiple tau species including p-tau181, [p-tau217](/biomarkers/p-tau-217), and p-tau231, with reduced insoluble aggregated tau in mouse models[@arvinas].

Dual PROTACs: Compounds like T3 simultaneously degrade both [alpha-synuclein](/proteins/alpha-synuclein) and tau, addressing copathology common in neurodegeneration[@gao2024].

alpha-Synuclein (Parkinson's Disease, DLB, MSA)

[alpha-synuclein](/proteins/alpha-synuclein) aggregation into [Lewy bodies](/mechanisms/lewy-body-formation) characterizes [Parkinson's disease](/diseases/parkinsons-disease), [Lewy body dementia](/diseases/lewy-body-dementia), and [multiple system atrophy](/diseases/multiple-system-atrophy).

PROTACs targeting alpha-synuclein have demonstrated:

DC50 values in low nanomolar range
Degradation approaching 80% for lead molecules
Selective clearance of oligomeric and fibrillar forms[@gao2024]

TDP-43 (ALS, FTLD)

[TDP-43](/proteins/tdp-43) proteinopathy characterizes approximately 97% of [ALS](/diseases/amyotrophic-lateral-sclerosis) and ~50% of [FTD](/diseases/frontotemporal-dementia) cases. PROTACs targeting mislocalized or aggregated [TDP-43](/mechanisms/tdp-43-proteinopathy) are in early preclinical development.

Molecular glue approaches for TDP-43 include:

Inducers of nuclear import: Small molecules promoting TDP-43 nuclear localization
Aggregation inhibitors: Compounds preventing stress granule sequestration

LRRK2 (Parkinson's Disease)

[LRRK2](/proteins/lrrk2-protein) mutations are the most common genetic cause of familial [Parkinson's disease](/diseases/parkinsons-disease). ARV-102 is the most clinically advanced CNS PROTAC:

Orally bioavailable, brain-penetrant
Degraded LRRK2 by nearly 90% in non-human primate brain
Demonstrated CSF drug levels confirming [BBB](/entities/blood-brain-barrier) penetration
Phase 1b trial in PSP planned for 2026[@arvinas2025]

Mutant Huntingtin (Huntington's Disease)

PROTACs can selectively degrade mutant [huntingtin](/proteins/huntingtin) while sparing wild-type protein — a key advantage over [antisense oligonucleotides](/therapeutics/antisense-oligonucleotide-therapies) like tominersen that reduce both forms.

Delivery Challenges for CNS

Blood-Brain Barrier Penetration

PROTACs' larger molecular weight (700-1000 Da) poses significant BBB challenges. Strategies to improve penetration include:

Target Selectivity

Achieving selective degradation of pathological protein species while sparing physiological forms is critical:

Conformation-selective warheads: Bind preferentially to aggregated/modified forms
Tissue-specific E3 ligases: Limit degradation to affected brain regions
Context-dependent degradation: Only in cells with high target levels

Hook Effect

At high concentrations, PROTACs can saturate both target and E3 ligase separately, preventing ternary complex formation. This inverted U-shaped dose-response requires careful clinical dosing optimization.

Clinical Development Landscape

Lysosome-Targeting Chimeras (LYTACs)

LYTACs redirect extracellular and membrane proteins to lysosomes via mannose-6-phosphate receptors. Particularly useful for:

Extracellular [amyloid-beta](/proteins/amyloid-beta)
Secreted alpha-synuclein
Membrane protein targets

Autophagy-Targeting Chimeras (AUTACs)

AUTACs leverage [autophagy](/entities/autophagy) for degradation, essential for large protein aggregates that exceed proteasome capacity. Particularly relevant for:

Large fibrils and inclusions
Mitochondrial clearance
Aggresome targeting

Antibody-Based Degraders (AbTACs)

Bispecific antibodies recruiting membrane E3 ligases (RNF43) for degradation of cell-surface and extracellular targets.

Future Directions

The field is rapidly evolving toward:

Oral brain-penetrant degraders: ARV-102 as template

Multi-target approaches: Dual PROTACs addressing copathology

Combination therapies: With immunotherapy, gene therapy, autophagy enhancers

Biomarker-guided development: CSF p-tau, [NfL](/biomarkers/neurofilament-light-chain-nfl), α-synuclein seeding

Patient stratification: Genetic testing for target selection

References

[Klein et al., Molecular glue degraders: a new paradigm for targeted protein degradation (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38493520/)

Unknown, Arvinas Neuroscience Pipeline — Tau, alpha-synuclein, and mHTT PROTAC Programs (n.d.)

[Gao et al., Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38356330/)

Unknown, Arvinas, First-in-Human Data for ARV-102 Demonstrating Blood-Brain Barrier Penetration and LRRK2 Degradation (2025) (2025)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

PROTACs and Molecular Glues for Neurodegeneration

PROTACs and Molecular Glues for Neurodegeneration

Overview

PROTACs and Molecular Glues for Neurodegeneration

Overview

Mechanism of Action

PROTAC Heterobifunctional Degraders

Molecular Glue Degraders

CNS Targets for Neurodegeneration

Tau Protein (Alzheimer's Disease and Tauopathies)

alpha-Synuclein (Parkinson's Disease, DLB, MSA)

TDP-43 (ALS, FTLD)

LRRK2 (Parkinson's Disease)

Mutant Huntingtin (Huntington's Disease)

Delivery Challenges for CNS

Blood-Brain Barrier Penetration

Target Selectivity

Hook Effect

Clinical Development Landscape

Related Technologies

Lysosome-Targeting Chimeras (LYTACs)

Autophagy-Targeting Chimeras (AUTACs)

Antibody-Based Degraders (AbTACs)

Future Directions

See Also

References

Related Hypotheses